Table: What's in Store for J&J?
Possible targets for the health-care giant:
Its new drug for heart failure could bring in $500 million a year.
Its new HIV drug is off to a good start. Some analysts believe it could generate close to $1 billion in sales.
Provigil, its fast-growing drug for narcolepsy, may eventually be used for a range of other sleep disorders--and garner $700 million in sales.
A drug in the works for angina could be worth $500 million a year.